Robot helps replace woman's hip
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
44 minutes ago
- CTV News
Child-care centre to open in Lethbridge in the fall
Calgary Watch A new child-care centre is now under construction, and when it opens in the fall, it will be the first facility in Lethbridge to offer 24-hour care.
CTV News
an hour ago
- CTV News
Canadians with Down syndrome living longer: study
Winnipeg Watch A new study into the mortality rate of people living with Down syndrome leads MedicalWatch for July 17, 2025.
CBC
an hour ago
- CBC
B.C. limits sale of 2 more diabetes drugs used for weight loss
British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs in an attempt to curb their off-label use for weight loss and preserve supply for people who are diabetic. The rule bans pharmacies from selling tirzepatide (sold as Mounjaro) and dulaglutide (sold as Trulicity) to non-Canadians or non-permanent residents who don't go in person to pick up the medications. The two drugs are being added to an existing regulation first announced in 2023, which limits sales of semaglutide, a medication sold under the brand names Ozempic, Wegovy, and Rybelsus. The medications are still available to non-Canadians with a valid prescription from a Canadian doctor or nurse practitioner as long as they go to pick up the medication in person, according to a statement from the ministry. They are also still available from B.C. pharmacies, online or in person, to B.C. residents, Canadian citizens and permanent residents who have a valid prescription. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Dr. Tom Elliott, medical director at B.C. Diabetes, says that semaglutide injections have revolutionized his practice, and they are astonishingly effective. Health Minister Josie Osborne says the drugs' use for weight loss is driving shortages in several countries, including the United States. "Tirzepatide, dulaglutide and semaglutide are prescription drugs approved for the management of Type 2 diabetes, but their off-label use for weight loss is driving shortages of the drugs in several countries, including the United States," she said in a press release.
